search
Back to results

Early Detection of COVID-19 Using Breath Analysis - Feasibility Study (COVID-19)

Primary Purpose

Covid19

Status
Completed
Phase
Not Applicable
Locations
Israel
Study Type
Interventional
Intervention
Breath Biopsy
Sponsored by
Scentech Medical Technologies Ltd
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Covid19

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

Hospitalized group:

  • Age 18 to 75 years at the time of consent
  • Positive results for SARS-CoV-2
  • Capable of understanding written and/or spoken language
  • Able to provide informed consent
  • Was not treated with Anti-viral drugs
  • Not a pregnant woman

Healthy group:

  • Healthy volunteers
  • Age 18 to 75 years at the time of consent
  • No history of COVID-19
  • Capable of understanding written and/or spoken language
  • Able to provide informed consent
  • Was not treated with Anti-viral drugs
  • Not a pregnant woman

Sexes Eligible for Study: All

Exclusion Criteria:

Hospitalized group:

  • Age under 18 years old
  • (Anticipated) inability to complete breath sampling procedure due to e.g. hyper- or hypoventilation, respiratory failure or claustrophobia when wearing the sampling mask
  • Persons under guardianship or deprived of liberty
  • Patients with the following diseases: Cancer, Asthma, Chronic Respiratory Disease

Healthy group:

  • Age under 18 years old
  • History of COVID-19
  • Persons under guardianship or deprived of liberty
  • Subjects with the following diseases: Cancer, Asthma, Chronic Respiratory Disease

Sites / Locations

  • Soroka Medical Center
  • Meir Medical Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Other

Arm Label

COVID 19 Positive patients

Healthy subjects

Arm Description

Patients with COVID-19, qPCR for SARS-CoV-2 confirmed

COVID-19 Negative subjects

Outcomes

Primary Outcome Measures

Correlation between Volatile Organic Compounds pattern in-breath biopsy and COVID-19 detection.
Correlation between Volatile Organic Compounds found in breath biopsy chromatography and COVID-19 detection in a swab test.

Secondary Outcome Measures

Correlation between Volatile Organic Compounds pattern and the course of the disease
Correlation between Volatile Organic Compounds found in breath biopsy chromatography and COVID-19 detection intensity in a swab test.

Full Information

First Posted
October 21, 2020
Last Updated
May 9, 2022
Sponsor
Scentech Medical Technologies Ltd
search

1. Study Identification

Unique Protocol Identification Number
NCT04602871
Brief Title
Early Detection of COVID-19 Using Breath Analysis - Feasibility Study
Acronym
COVID-19
Official Title
Early Detection of the 2019 Novel Coronavirus (SARS-CoV-2) Using Breath Analysis - Feasibility Study
Study Type
Interventional

2. Study Status

Record Verification Date
October 2020
Overall Recruitment Status
Completed
Study Start Date
July 3, 2020 (Actual)
Primary Completion Date
January 30, 2021 (Actual)
Study Completion Date
January 30, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Scentech Medical Technologies Ltd

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Early Detection of COVID-19 Using Breath Analysis -Feasibility Study.
Detailed Description
An interventional diagnostic prospective study study with risks and minimal constraints.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Covid19

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
54 (Actual)

8. Arms, Groups, and Interventions

Arm Title
COVID 19 Positive patients
Arm Type
Experimental
Arm Description
Patients with COVID-19, qPCR for SARS-CoV-2 confirmed
Arm Title
Healthy subjects
Arm Type
Other
Arm Description
COVID-19 Negative subjects
Intervention Type
Diagnostic Test
Intervention Name(s)
Breath Biopsy
Intervention Description
Breath Biopsy sampling using the ReCIVA® Breath Sampler
Primary Outcome Measure Information:
Title
Correlation between Volatile Organic Compounds pattern in-breath biopsy and COVID-19 detection.
Description
Correlation between Volatile Organic Compounds found in breath biopsy chromatography and COVID-19 detection in a swab test.
Time Frame
Through the study completion, up to 3 months.
Secondary Outcome Measure Information:
Title
Correlation between Volatile Organic Compounds pattern and the course of the disease
Description
Correlation between Volatile Organic Compounds found in breath biopsy chromatography and COVID-19 detection intensity in a swab test.
Time Frame
Through the study completion, up to 3 months.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Hospitalized group: Age 18 to 75 years at the time of consent Positive results for SARS-CoV-2 Capable of understanding written and/or spoken language Able to provide informed consent Was not treated with Anti-viral drugs Not a pregnant woman Healthy group: Healthy volunteers Age 18 to 75 years at the time of consent No history of COVID-19 Capable of understanding written and/or spoken language Able to provide informed consent Was not treated with Anti-viral drugs Not a pregnant woman Sexes Eligible for Study: All Exclusion Criteria: Hospitalized group: Age under 18 years old (Anticipated) inability to complete breath sampling procedure due to e.g. hyper- or hypoventilation, respiratory failure or claustrophobia when wearing the sampling mask Persons under guardianship or deprived of liberty Patients with the following diseases: Cancer, Asthma, Chronic Respiratory Disease Healthy group: Age under 18 years old History of COVID-19 Persons under guardianship or deprived of liberty Subjects with the following diseases: Cancer, Asthma, Chronic Respiratory Disease
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
David Shitrit, MD
Organizational Affiliation
Meir Medical Center, Kfar Saba, Israel
Official's Role
Principal Investigator
Facility Information:
Facility Name
Soroka Medical Center
City
Be'er Sheva
Country
Israel
Facility Name
Meir Medical Center
City
Kfar Saba
Country
Israel

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
No IPDs are to be shared with other researchers.

Learn more about this trial

Early Detection of COVID-19 Using Breath Analysis - Feasibility Study

We'll reach out to this number within 24 hrs